FORM PTO 1449 (r	S. DEPARTMENT OF CO	AMERIE E	SC139	ATTY DOCKET NO. 01997.026000.2	APPLICA 09/85	TION NO. 2,400		
LIST OF	ATENT AND TRADEMARK REFERENCES CITED BY (Use several sheets if nex	UFFICE		APPLICANT WILLIAM L. TREPICCHIO ET	AL.			
	(OSO GOLGIA) GIGORA II IIOCA	\ _	☆ /	FILING DATE May 9, 2001		GROUP 1634		
		CAT S. TRA	O.	U.S. PATENT DOCUMENTS				
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE	
			FOF	REIGN PATENT DOCUMENTS				
	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT	
	·	OTHER DOCUM	JENT(S)	Including Author, Title, Date, Pertinent Pages, E		11		
PN	GenBank dat complete cds	abase acces		no. U09770 "Human cysteine-ri		tein (hCRH	P) mRNA,	
	GenBank dat mRNA, comp	GenBank database accession no. U58630 "Human cysteine-rich intestinal protein (CRIP) mRNA, complete cds."						
	PARK et al. (Jan. 1999) "Vitamin D receptor polymorphism is associated with psoriasis", J. Invest. Dermatol., vol. 112, no. 1, pp. 113-16.							
	PINCELLI (Ma Dermatol., vo	PINCELLI (Mar. 2000) "Nerve growth factor and keratinocytes: a role in psoriasis", Eur. J. Dermatol., vol. 10, no. 2, pp. 85-90.						
V	KHOO et al. (1996) "Differential expression of cysteine-rich intestinal protein in liver and intestine in CCl₄-induced inflammation", Am. J. Physiol., vol. 270, pp. G613-18.							
EXAMINER P.	NOC			DATE CONSIDERED 6/28	104			

Sheet	1	of	1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	(3				_	<u> </u>		Shee	t 1 of 2	
REV 7-	-80		E OF FORM PTO-1449		TRADEMARK OFFICE	GFN-5405CP	3	09/852,400		
ı	LIST	OF H	PUBLICATIONS CIT			William L. Trepic	chio et al		CEN	JAN
		<u> </u>	र् हो			FILING DATE May 9, 2001		1623	哥	0 7
			0 2 2002	U.S. PA	ATENT DOC	UMENTS			600/	2002
EXAM! INIT!	MER AL	Ž	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	CDUNG CEAPPRO	DATE OPRIATE
	丄	1	THAUE							
				FOREIGN	PATENT DO	OCUMENTS_				
	l		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSI	ATION NO
									120	
			OTHERS (inc	cluding Aut	hor, Title, Da	te, Pertinent Pages,	Etc.)			
Pn	A1		Balendran N, et a	l. Charact	erization of	the major suscepti	bility reg	ion for pso	riasis a	ıt
	1 A2	+				l. 1999 Sep;113(3) ng for primary defe				
1									7	
+	A3	十	dehydrogenase E1alpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7 Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on							
\bot		1				ım Genet, 1999 De				
	A4	1				oduces superior cli				
		1				sis in patients com	pared wi	th broadbai	nd UV	·В.
+-	A5			Arch Dermatol. 1997 Dec; 133(12):1514-22						J
			Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40						n in	
	A6	+	Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc							
			Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8							
	Α7	1	Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica.						ca.	
			1978;157(4):238-44							
	A8	1	Golub TR, et al. Molecular classification of cancer: class discovery and class prediction							
44	40	4				. 1999 Oct 15;286			i.	
1	A9		Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995					2)		
				/ immune,	, but not ker	atinocyte, pathoge	nic basis.	. Nat Med.	1995	
May;1(5):442-7 Gottlieb AB, et al. Studies of the effect of cyclosporine in pso						· · · · · · · · · · · · · · · · · · ·		.1		
W.			effects on activate							α
	, ,,,,,		Dermatol. 1992 M			cprdcrmar.regener	all v.CIIIai	uranom, j i	nvest	
xami	ner	0	Nolan	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Date Considered	,			· · · · · ·
						6/28/	04			
EXAN	MINER	₹:	Initial if reference citation if not in c	considered, conformance	whether or not o	citation is in conformance red. Include copy of this	with MPEP form with ne	609; Draw fine	through ion to ap	plicant.

*	2.		-	Sheet 2	of 2-4
APPLICANT REV 7-80	FACSIMILE	OF FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.	*
LIS	TOF F	PUBLICATIONS CITED BY APPLICANT	GFN-5405CP	69/852,400	
1	P E(several sheets if necessary)	William L. Trepicchio et		ENT
VO.	-000		May 9, 2001	1623	ш.
HAL	0 5 5mm				1600/
WAT:	D:4	OTHERS (including Author, Title, Dat			600/2900
DA C	TRADE!	Krueger JG, et al. Role of growth factor pathogenesis of psoriasis. J Invest Dern	rs, cytokines, and their rec	eptors in the	8
PN E	32	Tamayo P, et al. Interpreting patterns of			
PN		methods and application to hematopoie 1999 Mar 16;96(6):2907-12	tic differentiation. Proc Na	atl Acad Sci U	s A.
PN	33	Trepicchio WL, et al. Interleukin-11 the proinflammatory pathways in psoriasis	erapy selectively downregoresions. J Clin Invest. 199	ulates type I cy 9 Dec;104(11):	tokine 1527-37
PN	34	Trepicchio WL, et al. IL-11 regulates m inhibition of nuclear factor-kappaB. J In	nacrophage effector function	on through the	
				· · · · · · · · · · · · · · · · · · ·	
	\dashv				
	-		V .	<i>'</i>	
	$ \square$				
	$\perp \perp$				
					
					
-+-	+				
					·····
\bot	\dashv				
			9. A		
Examiner	Poti	nor J-Nor	ate Considered 6/28/04		
EXAMINE	ER:	Initial if reference considered, whether or not c citation if not in conformance and not consider	itation is in conformance with MPEF	609; Draw line thro	ugh n applicant